Rallybio Corp

NASDAQ RLYB

Data sourced from

and

Download Data

Rallybio Corp Asset Turnover Ratio 1 year YoY Change (%) for the Trailing 12 Months (TTM) ending September 20, 2024

Rallybio Corp Asset Turnover Ratio 1 year YoY Change (%) is NA for the Trailing 12 Months (TTM) ending September 20, 2024. The asset turnover ratio measures a company's efficiency in utilizing its assets to generate revenue. It is calculated by dividing the company's revenue by the average of its total assets and total non-current assets. This ratio indicates how effectively a company generates sales from its asset base. A higher ratio implies better asset utilization and revenue generation, while a lower ratio may suggest underutilization of assets or inefficient operations. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Rallybio Corp Asset Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00, a 0.00% change year over year.
Rallybio Corp Asset Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2022 was 0.00, a 0.00% change year over year.
Rallybio Corp Asset Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2021 was 0.00.

NASDAQ: RLYB

Rallybio Corp

CEO	Dr. Martin W. MacKay Ph.D.
IPO Date	July 29, 2021
Location	United States
Headquarters	234 Church Street, New Haven, CT, United States, 06510
Employees	30
Sector	Healthcare
Industry	Biotechnology

Description

Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.

Key trends